A Phase I, Double-Blind, Randomized, Placebo-Controlled Ascending IV Single-Dose Tolerance and Pharmacokinetic Study of Trodusquemine (MSI-1436) in Obese Type 2 Diabetics
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2008
At a glance
- Drugs Trodusquemine (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics
- Sponsors Genaera Corporation
- 09 Dec 2008 Status changed from recruiting to completed, based on information from ClinicalTrials.gov.
- 25 Jul 2008 Interim safety and pharmacokinetic data have been reported at the CBI 4th Annual Obesity Drug Development Summit in Arlington, Virginia, USA, according to a Genaera Corporation media release.
- 17 Jan 2008 Patient dosing has been initiated.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History